deuteriumremidvir

Deuteriumremidvir refers to a deuterated analogue of remdesivir, an antiviral drug originally developed for the treatment of COVID-19. Deuteration involves replacing certain hydrogen atoms in the molecule with deuterium, a stable isotope of hydrogen. This modification can improve metabolic stability and pharmacokinetic properties without significantly altering the drug’s mechanism of action. Like remdesivir, deuteriumremidvir is expected to act as a nucleoside analog prodrug that inhibits viral RNA-dependent RNA polymerase (RdRp), thereby blocking viral replication. The parent compound, remdesivir, is approved for use against SARS-CoV-2 infection and works by causing delayed chain termination during viral RNA synthesis[6][8]. Deuterated analogues have been synthesized and shown to retain similar antiviral activity in vitro against SARS-CoV-2[4][3]. These modifications are under investigation for potential improvements in oral bioavailability and therapeutic profile.

Other names

deuterated remdesivir